Roth Capital Partners Facilitates CapsoVision's $27.5 Million IPO

Roth Capital Partners served as joint book-running manager for the initial public offering of CapsoVision, Inc., a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions. The offering comprised 5,500,000 shares of common stock priced at $5.00 per share, generating approximately $27.5 million in gross proceeds before deductions. Trading of CapsoVision's shares commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol 'CV'. Additionally, the underwriters were granted a 30-day option to purchase up to an extra 825,000 shares at the IPO price. This development underscores the growing investor confidence in innovative medical technologies and the critical role of financial institutions like Roth Capital Partners in facilitating access to capital for growth-oriented companies.